However, the execution of sentence shall be suspended for a period of two years from the date this judgment becomes final and conclusive.

1. The Defendant is not a handler of narcotics, etc.

A. On November 24, 2016, around 23:30 on November 24, 2016, the Defendant, along with the 106-dong 1703, Seongdong-gu Seoul Metropolitan Government apartment building B, 106-dong 1703, C, D, and E, administered the fluor non-fluoric volume of the fluor non-pharmaceuticals (GHB; hereinafter “GHB”), by mixing the fluoric volume with the fluor’s beverages in paper cup

B. On November 26, 2016, around 01:00, the Defendant administered GHB’s in a manner of drinking with the place indicated in the foregoing paragraph 1’s (A), C, D, E, F, etc., by mixing GHB’s unsound with the non-commercial beverage contained in the paper instant cups.

2. The Defendant is not a narcotics handler.

On November 26, 2016, around 00:30, the Defendant administered the drugs in such a way as to put them into the reflector of MDMA (one name “Empter”), which is a local mental medicine received from D, and to take them together with water.

3. No person ingested marijuana shall smoke or take in marijuana or its seed coats;

On November 25, 2016, at around 06:00, the Defendant taken marijuana at the place indicated in the foregoing paragraph 1-A, and at the place specified in C, the Defendant taken marijuana in the manner of drinking it by chewing.

4. The Defendant is not a handler of narcotics.

On November 26, 2016, the Defendant: (a) received marijuana 1-A at the place specified in the new wall hours, and (b) received from D, from E, for the fluorian fluorian fluorian fluorian fluoral quantity (the fluoral 1-2 eluoral fluor).

Summary of Evidence

1. Statement by the defendant in court;

1. A protocol concerning the interrogation of each police suspect against C, D, F, and E;

1. Application of Acts and subordinate statutes to a criminal investigation report (report on attachment to a judgment) and a criminal investigation report (report on market price related to additional collection charges);

1. Article 61(1)5, Article 4(1)1, Article 2 subparag. 3(d) (GHB medication) of the Act on the Control of Narcotics, Etc., Article 60(1)2, Article 4(1)1, Article 4(1)3(b) of the Act on the Control of Narcotics, Etc., Article 2 subparag. 3(d) of the Act on the Management of Narcotics, Etc., Article 60(1)1, Article 4(1)3(b) of the Act on the Management of Narcotics, Etc., and Article 2 subparag. 3(b) of the Act on the Management of Narcotics, Etc.